Conference Call with Windlas Biotech Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Windlas Biotech announced Q1FY26 results Revenue from operations stood at Rs 210.1 crore as against Rs 175.2 crore, a growth of 19.9% YoY. EBITDA stood at Rs 26.5 crore as against Rs 20.9 crore, a growth of 27.0% YoY. EBITDA Margin (%) came in at 12.6%. PAT stood at Rs 17.7 crore as against Rs 13.5 crore, a growth of 31.1% YoY. PAT Margin (%) came in at 8.4%. Hitesh Windlass, Managing Director, Windlas Biotech, said: “This quarter reinforces our strong growth trajectory, marking the tenth successive quarter of record revenue performance. The Company reported an earnings per share (EPS) of Rs 8.4 for Q1FY26, marking a 30% YoY increase. In line with its commitment to shareholder value creation, the Board paid a dividend of Rs 12.2 crore (Rs 5.8 per share) to its shareholders for FY25 in August 2025. The Indian Pharmaceutical Market (IPM) registered a YoY growth of 9% in Q1FY26, with a modest volume growth of 1%. We delivered 19.9% YoY revenue growth for the quarter, driven by steady contributions from all three business verticals. Our Generic Formulations CDMO vertical continues to deliver healthy performance, driven by customer additions, expansion in product portfolio, and consistent delivery of quality manufacturing products. The Trade Generics and Institutional vertical sustained their growth momentum through deeper penetration across core and adjacent markets, supported by government healthcare schemes such as Ayushman Bharat and Jan Aushadhi. In exports, we are actively pursuing several strategic initiatives aimed at meeting the increasing global demand for high-quality and affordable generic medicines. On the manufacturing front, we are strengthening our operational infrastructure through the upgrade of our recently acquired Plant 6, which remains on schedule for its planned capacity expansion. Additionally, our injectable facility is enhancing our ability to serve diverse customer needs and deliver a wider range of products efficiently. As we move ahead, our outlook on the broader Indian pharmaceutical sector remains optimistic. Our focus remains on driving long-term value for shareholders by boosting operational efficiencies, nurturing key talent, and expanding our dosage form capabilities.” Komal Gupta, CEO & CFO, Windlas Biotech, said: “On the back of performance momentum seen consecutively across the last ten quarters, we delivered another quarter of consistent performance with revenue of Rs 210 crore., EBITDA Rs 27 crore, and PAT Rs 18 crore. The company recorded 20% YoY growth in revenue, 27% in EBITDA and 31% in PAT. The company’s gross margin expanded by 71 bps YoY to 38.3%, while EBITDA margin improved by 70 bps to 12.6%. Windlas Biotech is strategically focused on strengthening core capabilities and expanding into high-potential geographies to meet evolving market needs. Through disciplined execution and operational efficiency, we are well-positioned to drive sustainable growth, enhance competitiveness, and create long-term value for our shareholders. Our Generic Formulations CDMO vertical achieved growth of 17.8% YoY, contributing Rs 160 crore in revenue. Our continuous endeavour to ensure delivery excellence and stringent quality standards strengthens our positioning as a trusted CDMO partner in the pharmaceutical industry. The Trade Generics and Institutional vertical grew by 25.2% YoY to Rs 44 crore. This growth was driven by enhanced distribution reach, stronger market presence in previously underserved regions and increased product range. Exports vertical registered 45.4% YoY growth to Rs 6 crore, as we continue to deepen our presence in key regulated and semi-regulated markets. As we progress through FY26, the company remains focused on driving process enhancements and strengthening internal efficiencies. We are currently witnessing encouraging trends across all business verticals. Backed by a differentiated value proposition and strong customer engagement, the company is optimally structured to unlock its long-term goals in a sustainable and impactful manner.” Result PDF